|
시장보고서
상품코드
2086956
혈액 기반 바이오마커 시장 : 시장 인사이트, 경쟁 구도 및 시장 예측(2034년)Blood Based Biomarkers - Market Insights, Competitive Landscape, and Market Forecast - 2034 |
||||||
DelveInsight
혈액 기반 바이오마커 시장 요약
개요:
- 혈액 기반 바이오마커 시장은 2025년에 85억 달러로 평가되었고, 2034년까지 185억 달러에 달할 것으로 예측됩니다. 이러한 성장의 배경에는 암, 심혈관 질환, 신경계 질환의 부담 증가, 비침습적 검사로의 전환, 그리고 알츠하이머병에 대한 최초의 혈액 검사를 필두로 한 일련의 규제 당국 승인 물결이 있습니다.
- 세계의 혈액 기반 바이오마커 시장은 2026-2034년 예측 기간 동안 연평균 성장률(CAGR) 9.0%로 성장할 전망입니다.
- 유형별로는 2025년에 유전자 바이오마커 부문이 41%의 점유율을 차지하며 혈액 기반 바이오마커 시장을 주도했습니다.
- 용도별로는 2025년에 종양학 부문이 39%의 점유율을 차지하며 혈액 기반 바이오마커 시장을 주도했습니다.
- 기술별로는 2025년에 면역측정법 부문이 36%의 점유율을 차지하며 혈액 기반 바이오마커 시장을 주도했습니다.
- 최종 사용자별로는 2025년에 병원 및 진단실험실 부문이 혈액 기반 바이오마커 시장에서 48%의 점유율을 차지하며 시장을 주도했습니다.
- 북미는 2025년에 44%의 점유율을 차지하며 세계 혈액 기반 바이오마커 시장의 매출을 견인했고, 지역별로는 세계에서 가장 높은 시장 점유율을 기록했습니다.
혈액 기반 바이오마커란 혈액 내에 존재하는 측정 가능한 생물학적 지표를 말하며, 단백질, 핵산, 세포, 대사 산물 등이 포함되며, 개인의 건강 상태, 질환 유무 및 진행 상황, 치료 반응에 관한 정보를 제공합니다. 저침습적인 채혈을 통해 검출되는 이러한 바이오마커에는 세포 유래 DNA, 순환 종양 DNA, 마이크로RNA 등의 유전적 마커, 트로포닌, 인산화 타우, 전립선 특이 항원(PSA) 등의 단백질 마커, 순환 종양 세포 및 기타 세포, 그리고 포도당이나 당화 헤모글로빈 등의 대사 산물이 포함됩니다. 이들은 암, 심혈관 질환, 신경계 질환, 대사성 질환, 감염증의 조기 발견, 진단, 경과 관찰 및 관리에서 점점 더 중요한 역할을 수행하고 있으며, 동반 진단, 재발 모니터링, 임상시험 대상자 선정을 지원하고 있습니다. 이 시장은 바이오마커의 유형, 면역측정법, 중합효소연쇄반응(PCR), 차세대 염기서열 분석, 질량 분석법 등의 검출 기술, 그리고 병원, 진단 및 검사 기관, 연구 기관에 이르는 광범위한 용도 분야에 걸쳐 있습니다. 만성 질환 및 노화 관련 질환의 부담 증가, 체액 생검의 성숙, 알츠하이머병 혈액 검사 분야의 혁신적인 흐름, 그리고 침습적인 조직 생검에서 신속·안전·반복 가능한 혈액 검사로의 광범위한 전환에 힘입어, 혈액 유래 바이오마커는 정밀의료 및 예방 의료의 기반이 되는 인프라로 자리 잡고 있습니다.
혈액 기반 바이오마커 시장의 주요 성장 촉진요인
- 세계적으로 암 부담이 증가함에 따라 혈액 기반 암 바이오마커에 대한 수요가 견인되고 있으며, 국제암연구소(IARC)는 암 환자 수가 2022년 2,000만 명에서 2050년까지 3,500만 명으로 증가할 것으로 예측했습니다.
- 알츠하이머병 및 파킨슨병과 같은 신경 질환의 유병률 증가와 고령화 추세가 맞물려, 비침습적인 혈액 기반 진단법에 대한 수요를 견인하고 있습니다.
- 2025년에 알츠하이머병 진단을 지원하는 최초의 FDA 승인 혈액 검사를 포함하여, 혈액 검사와 관련된 규제 승인의 혁신적인 물결이 임상 현장의 도입을 가속화하고 있습니다.
- 액체 생검 기술의 성숙으로 인해 암의 검출, 치료법 선택, 재발 모니터링을 목적으로 하는 순환 종양 DNA의 고감도 검출이 가능해졌습니다.
- 침습적인 조직 생검에서 보다 신속하고 안전하며 반복 가능한 혈액 검사로의 광범위한 전환에 따라, 선별 검사, 진단, 모니터링 각 분야에서의 채택이 확대되고 있습니다.
- 인공지능, 단백질체학 및 멀티 바이오마커 패널의 발전으로 정확도가 향상되어, 예측적이고 위험도에 기반한 정밀 진단이 가능해졌습니다.
- 질병 부담, 비침습적 검사, 규제 측면의 진전 및 기술 발전이 맞물려, 2034년까지 시장은 강력한 성장을 유지할 것으로 예측됩니다.
혈액 기반 바이오마커 시장의 성장에 기여하는 요인
시장 성장 촉진요인
세계 암 부담 증가 및 액체 생검의 보급
혈액 기반 바이오마커 시장의 가장 강력한 촉진요인은 세계 암 부담 증가와 이에 따른 액체 생검의 급속한 보급입니다. 국제암연구소(IARC)의 기록에 따르면, 2022년 신규 암 환자 수는 2,000만 명이며, 2050년까지 3,500만 명에 달할 것으로 예측됩니다. 또한, 혈액 기반 바이오마커의 최대 용도 분야는 종양학입니다. 액체 생검을 통해 많은 경우 돌연변이 대립유전자 빈도가 낮은 상태에서도 순환 종양 DNA를 고감도로 검출할 수 있게 되어, 침습적인 조직 채취 없이 조기 발견, 치료법 선택, 재발 모니터링을 지원합니다. 임상 연구에 따르면, 진행성 암 환자의 상당수가 혈액 검사를 통해서만 검출 가능한, 치료 방침 결정에 도움이 되는 순환 종양 DNA의 돌연변이(치료 저항성 돌연변이 포함)를 가지고 있는 것으로 나타났습니다. 순환 종양 DNA 및 무세포 DNA(cfDNA)와 같은 유전적 바이오마커가 시장의 최대 부문을 차지하고 있습니다. 암 발병률이 증가하고 체액 생검 기술이 성숙해짐에 따라, 혈액 기반 종양학 바이오마커에 대한 수요는 확대될 것이며, 예측 기간 동안 시장의 성장을 뒷받침할 것으로 전망됩니다.
신경 질환 부담 증가와 알츠하이머병 혈액 검사의 혁명
알츠하이머병과 파킨슨병으로 대표되는 신경 질환의 부담 증가는 시장을 견인하는 가장 빠르게 성장하는 촉진요인입니다. 인구 고령화에 따라 치매 및 신경퇴행성 질환의 유병률이 증가하고 있으며, 혈액 검사를 통한 바이오마커는 고비용의 아밀로이드 양전자 방출 단층 촬영(PET)이나 뇌척수액 검사를 대체할 수 있는 보다 간편하고 신속하며 침습성이 낮은 대안을 제공합니다. 알츠하이머병 혈액 검사에는 혁신적인 변화가 일어나고 있으며, 그 중심에는 pTau217 및 pTau181과 같은 인산화 타우(pTau) 바이오마커가 있습니다. 이들은 아밀로이드 및 타우 병리를 검출하는 측면에서 기존 검사법을 일관되게 능가하는 성능을 보여주고 있습니다. 알츠하이머병 진단을 지원하는 최초의 FDA 승인 혈액 검사가 2025년에 미국 시장에 등장했으며, 현재 전문 학회 지침에서는 선별 검사 및 적절한 환자의 경우 영상 진단이나 뇌척수액 검사를 대체하는 고성능 혈액 검사가 권장되고 있습니다. 또한 세계보건기구(WHO)도 이러한 진단법에 관한 권장 제품 특성을 발표했습니다. 이러한 질병 부담, 임상적 타당성 및 가이드라인에 따른 지지가 맞물려, 예측 기간 동안 신경 질환 혈액 기반 바이오마커에 대한 수요가 급속히 확대되고 있습니다.
시장 제약 요인
강력한 성장세를 보이고 있음에도 불구하고, 혈액 기반 바이오마커 시장은 중대한 제약에 직면해 있습니다. 혈액 검사는 다양한 집단과 질환의 진행 단계에서 높은 민감도와 특이도를 입증해야 하기 때문에 분석적 및 임상적 검증 요건이 엄격하며, 많은 바이오마커는 질환의 초기 단계에서 민감도가 낮아지는 경향이 있습니다. 이로 인해 잘못된 안도감을 주는 위음성 결과나, 비용이 많이 들고 불안을 야기하는 재검사를 유발하는 위양성 위험이 높아지고 있습니다. 지역 및 용도에 따라 보험 환급 상황은 여전히 불균일하고 미성숙한 상태이며, 많은 첨단 검사는 보험사나 공적 보험의 광범위한 적용 대상에서 제외되어 본인 부담 또는 검사실 독자 개발 검사(LDT)로 제공되고 있기 때문에 접근성과 투자 수익률이 제한되고 있습니다. 규제 체계는 특히 신규 검사나 다항목 검사의 경우 여전히 발전 단계에 있기 때문에 개발 기간이 길어지고 불확실성이 높아지고 있습니다. 또한, 많은 검사가 승인되지 않아 진료 지침에 반영되는 데 제한이 있습니다. 플랫폼, 분석법, 기준 범위에 걸친 표준화 및 조화의 미비는 비교 가능성과 임상적 해석을 복잡하게 만들고 있으며, 일부 상황에서는 확인을 위한 영상 진단이나 조직 검사가 필요하기 때문에 단독 사용이 제한되고 있습니다. 첨단 플랫폼의 높은 비용과 전문적인 인프라 및 전문 지식의 필요성은 특히 자원이 부족한 환경에서 도입을 저해하고 있으며, 데이터 개인정보 보호, 거버넌스, 형평성에 관한 고려 사항도 복잡성을 더하고 있습니다. 임상의와 환자의 인식은 여전히 고르지 않으며, 장기적인 근거가 확보될 때까지 실제 치료 결과에 미치는 영향에 대한 불확실성이 보급을 저해하고 있습니다. 이러한 검증, 보험 환급, 규제, 표준화, 인프라와 관련된 장벽들이 복합적으로 작용하여, 질병 부담과 비침습적 검사의 근본적인 촉진요인이 여전히 확고함에도 불구하고 시장 성장 속도를 둔화시키고 있습니다.
경쟁 구도는 다음과 같은 관점에서 평가할 수 있습니다.
- 시장 집중도 : 중간 정도의 집중도를 보이고 있으며, 대형 진단 기업 외에도 검사실 네트워크 및 액체 생검 및 신경 질환 분야의 전문 혁신 기업들이 참여하는 활기찬 시장이 형성되어 있습니다.
- 주요 기업 : Roche, Abbott, Siemens Healthineers, Thermo Fisher Scientific이 폭넓은 플랫폼과 임상적 근거를 무기로 상위권을 주도하고 있습니다.
- 지리적 확장 : 주요 기업들은 세계적인 판매 및 검사 네트워크를 구축하고 있으며, 북미, 유럽, 아시아태평양에서 확고한 입지를 다지고 있습니다.
- 제품 포트폴리오의 강점 : 주요 기업들은 종양학, 순환기학, 신경학 분야에 걸쳐 면역 분석법, 분자진단, 시퀀싱을 통합한 포트폴리오를 보유하고 있습니다.
- 파이프라인 및 근거의 강점 : 규제 당국의 승인이나 FDA가 최초로 승인한 알츠하이머병 혈액 검사와 같은 대규모 임상 데이터 세트는 결정적인 경쟁 우위를 제공합니다.
- 전략적 제휴 : 바이오젠과 벡만 콜터, 후지리바이오와의 제휴 등, 진단제 제조업체와 제약사의 협력을 통해 검사 개발이 가속화되고 있습니다.
- 인수합병(M&A) 활동 : 각사가 포트폴리오를 확대하기 위해 바이오마커 기술, 액체 생검, 신경퇴행성 질환 관련 역량을 확보하려는 움직임이 활발해지면서 업계 재편이 진행되고 있습니다.
- 기술 플랫폼 : 초고감도 면역측정법, 차세대 시퀀싱, 디지털 중합효소 연쇄반응(PCR), 질량 분석법이 각 공급업체의 차별화 요인으로 작용하고 있습니다.
- 혁신의 초점 : 액체 생검 및 순환 종양 DNA, 혈장 타우 신경 마커, 다중 바이오마커 패널, AI를 활용한 결과 해석.
혈액 기반 바이오마커 시장 보고서 조사에서 도출된 주요 포인트
- 현재 혈액 기반 바이오마커 시장 규모(2025년)에 대한 분석 및 9년간(2026-2034년) 시장 전망
- 지난 3년간 발생한 주요 제품 및 기술 개발, 합병, 인수, 제휴 및 합작 투자.
- 세계 혈액 기반 바이오마커 시장을 주도하는 주요 기업.
- 혈액 기반 바이오마커 시장에서 경쟁사들에게 열려 있는 다양한 기회.
- 2025년에 가장 호조를 보인 부문은 어디인가? 이러한 부문은 2034년에 어떤 추이를 보일까요?
- 현재 혈액 기반 바이오마커 시장에서 가장 호조를 보이는 지역 및 국가는 어디인가?
- 기업이 향후 혈액 기반 바이오마커 시장의 성장 기회에 집중해야 할 지역이나 국가는 어디인가?
본 혈액 기반 바이오마커 시장 보고서 조사를 통해 혜택을 얻을 수 있는 대상 독자
- 혈액 기반 바이오마커 제품을 제공하는 기업
- 조사 기관 및 컨설팅 회사
- 혈액 기반 바이오마커 관련 조직, 협회, 포럼 및 기타 협력 단체
- 정부 기관 및 기업
- 스타트업, 벤처 캐피털, 사모펀드
- 혈액 기반 바이오마커를 취급하는 유통업체 및 무역 회사
- 혈액 기반 바이오마커 시장 및 해당 시장의 최신 기술 동향에 대해 더 자세히 알고자 하는 다양한 최종 사용자.
자주 묻는 질문:
Q1. 혈액 기반 바이오마커 시장의 성장률은 어느 정도입니까?
혈액 기반 바이오마커 시장은 2026-2034년 예측 기간 동안 연평균 성장률(CAGR) 9.0%로 확대될 것으로 전망됩니다.
Q2. 혈액 기반 바이오마커 시장 규모는 어느 정도입니까?
혈액 기반 바이오마커 시장 규모는 2025년 85억 달러로 평가되었고, 2034년까지 185억 달러에 달할 것으로 예측됩니다.
Q3. 혈액 기반 바이오마커 시장을 주도하는 지역은 어디인가?
북미는 선진적인 인프라, 높은 의료비 지출, FDA가 최초로 승인한 알츠하이머병 혈액 검사를 포함한 규제 측면에서의 리더십, 그리고 진단 및 체액 생검 기업의 밀집된 기반을 바탕으로 2025년에는 세계 매출의 44%를 차지하며 혈액 기반 바이오마커 시장을 주도했습니다. 아시아태평양은 예측 기간 동안 가장 빠르게 성장할 지역입니다.
Q4. 혈액 기반 바이오마커 시장의 주요 촉진요인은 무엇인가?
주요 촉진요인은 세계적으로 증가하는 암 부담입니다. 국제암연구소(IARC)의 예측에 따르면, 암 환자 수는 2022년 2,000만 명에서 2050년까지 3,500만 명으로 증가할 것으로 예측됩니다. 신경 질환 부담 증가와 알츠하이머병 혈액 검사의 보급, FDA 승인의 가속화 및 전문 지침에 의한 지원, 액체 생검 기술의 성숙, 그리고 AI 및 다중 바이오마커 패널에 기반한 비침습적·예방적 검사로의 광범위한 전환을 들 수 있습니다.
Q5. 혈액 기반 바이오마커 시장의 주요 기업은?
주요 기업으로는 F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Bio-Rad Laboratories, Inc., Quanterix Corporation, Fujirebio Holdings, Inc., Guardant Health, Inc. 등이 있으며, 기타에도 ‘경쟁 구도’ 섹션에서 소개된 활발한 공급업체가 다수 존재합니다. Roche, Abbott, Siemens Healthineers, Thermo Fisher Scientific은 폭넓은 플랫폼과 임상적 근거를 무기로 시장을 선도하고 있습니다.
자주 묻는 질문
목차
제1장 혈액 기반 바이오마커 시장 보고서 서론
제2장 혈액 기반 바이오마커 시장 주요 요약
제3장 혈액 기반 바이오마커 시장의 주요 요인 분석
제4장 영향 분석 : AI, 지정학, 무역 및 경제 동향
제5장 규제 분석
제6장 혈액 기반 바이오마커 시장 : Porter's Five Forces 분석
제7장 혈액 기반 바이오마커 시장 평가
제8장 혈액 기반 바이오마커 시장 경쟁 구도
제9장 혈액 기반 바이오마커 시장 스타트업의 자금조달 및 투자 동향
제10장 혈액 기반 바이오마커 시장 : 기업 개요 및 제품 개요
제11장 KOL(Key Opinion Leader)의 견해
제12장 프로젝트 및 접근
제13장 DelveInsight에 대해
제14장 면책사항 및 문의
AJY 26.07.27Blood Based Biomarkers Market Summary
Overview:
- The Blood Based Biomarkers market is estimated at USD 8.50 billion in 2025 and is projected to reach USD 18.50 billion by 2034. Growth is anchored in the rising burden of cancer, cardiovascular, and neurological disease, the shift toward non-invasive testing, and a wave of regulatory clearances led by the first blood tests for Alzheimer's disease.
- The global Blood Based Biomarkers market is growing at a CAGR of 9.0% during the forecast period from 2026 to 2034.
- By type, the genetic biomarkers segment dominated the Blood Based Biomarkers market with a 41% share in 2025.
- By application, the oncology segment dominated the Blood Based Biomarkers market with a 39% share in 2025.
- By technology, the immunoassays segment dominated the Blood Based Biomarkers market with a 36% share in 2025.
- By end user, the hospital and diagnostic laboratories segment dominated the Blood Based Biomarkers market with a 48% share in 2025.
- North America dominated the global Blood Based Biomarkers market revenue with a 44% share in 2025, representing the highest regional market share globally.
Blood based biomarkers are measurable biological indicators in the blood, including proteins, nucleic acids, cells, and metabolites, that provide information about a person's health, disease presence and progression, and response to treatment. Detected through minimally invasive blood draws, these biomarkers include genetic markers such as cell-free DNA, circulating tumor DNA, and microRNA, protein markers such as troponin, phosphorylated tau, and prostate-specific antigen, circulating tumor and other cells, and metabolites such as glucose and glycated hemoglobin. They are increasingly central to the early detection, diagnosis, monitoring, and management of cancer, cardiovascular disease, neurological disorders, metabolic conditions, and infectious diseases, and they support companion diagnostics, recurrence monitoring, and clinical-trial enrichment. The market spans biomarker types, detection technologies including immunoassays, polymerase chain reaction, next-generation sequencing, and mass spectrometry, and applications across hospitals, diagnostic and reference laboratories, and research settings. Propelled by the rising burden of chronic and age-related disease, the maturation of liquid biopsy, a transformative wave of blood tests for Alzheimer's disease, and the broad shift from invasive tissue biopsy toward fast, safe, repeatable blood testing, blood based biomarkers have become foundational infrastructure for precision and preventive medicine.
Blood Based Biomarkers Market Key Growth Drivers
- The rising global cancer burden is driving demand for blood-based oncology biomarkers, with the International Agency for Research on Cancer projecting cancer cases to rise from 20 million in 2022 to 35 million by 2050.
- The growing prevalence of neurological disorders such as Alzheimer's and Parkinson's disease, alongside aging populations, is driving demand for non-invasive blood-based diagnostics.
- A transformative wave of regulatory clearances for blood tests, including the first FDA-cleared blood test to aid Alzheimer's diagnosis in 2025, is accelerating clinical adoption.
- The maturation of liquid biopsy is enabling sensitive detection of circulating tumor DNA for cancer detection, treatment selection, and recurrence monitoring.
- The broad shift from invasive tissue biopsy toward faster, safer, and repeatable blood testing is expanding adoption across screening, diagnosis, and monitoring.
- Advances in artificial intelligence, proteomics, and multi-biomarker panels are improving accuracy and enabling predictive, risk-based precision diagnostics.
- The convergence of disease burden, non-invasive testing, regulatory progress, and technological advances is expected to sustain strong growth in the market through 2034.
Key Companies in Blood Based Biomarkers Market
The competitive landscape is led by the following active developers and providers:
- F. Hoffmann-La Roche Ltd
- Abbott Laboratories
- Siemens Healthineers AG
- Thermo Fisher Scientific Inc.
- Quest Diagnostics Incorporated
- Laboratory Corporation of America Holdings
- Bio-Rad Laboratories, Inc.
- Quanterix Corporation
- Fujirebio Holdings, Inc.
- Guardant Health, Inc.
Factors Contributing to the Growth of the Blood Based Biomarkers Market
Market Drivers
Rising Global Cancer Burden and Liquid Biopsy Adoption
The most powerful driver of the blood based biomarkers market is the rising global cancer burden, coupled with the rapid adoption of liquid biopsy. The International Agency for Research on Cancer recorded 20 million new cancer cases in 2022 and projects 35 million by 2050, and oncology is the largest application for blood-based biomarkers. Liquid biopsy enables sensitive detection of circulating tumor DNA, often at low mutant allele frequencies, supporting early detection, treatment selection, and recurrence monitoring without invasive tissue sampling. Clinical studies have shown that a substantial share of advanced cancer patients carry actionable circulating tumor DNA mutations detectable only by blood-based testing, including resistance mutations that guide therapy. Genetic biomarkers such as circulating tumor DNA and cell-free DNA anchor the largest segment of the market. As cancer incidence climbs and liquid biopsy matures, demand for blood-based oncology biomarkers expands, anchoring market growth through the forecast period.
Growing Burden of Neurological Disease and the Alzheimer's Blood Test Revolution
The growing burden of neurological disease, led by Alzheimer's and Parkinson's, is the fastest-growing driver of the market. As populations age, the prevalence of dementia and neurodegenerative disorders rises, and blood-based biomarkers offer a simpler, faster, and less invasive alternative to costly amyloid positron-emission-tomography imaging and cerebrospinal-fluid testing. A transformative wave of blood tests for Alzheimer's has emerged, anchored by phosphorylated tau biomarkers such as pTau217 and pTau181, which consistently outperform earlier generations for detecting amyloid and tau pathology. The first FDA-cleared blood test to aid Alzheimer's diagnosis reached the United States market in 2025, professional-society guidelines now endorse high-performing blood tests for triage and, in appropriate patients, substitution for imaging or spinal-fluid testing, and the World Health Organization has issued preferred product characteristics for these diagnostics. This convergence of disease burden, clinical validation, and guideline support is rapidly expanding neurological blood-based biomarker demand across the forecast period.
Market Restraints
Despite strong momentum, the blood based biomarkers market faces material constraints. Analytical and clinical validation requirements are demanding, as blood-based tests must demonstrate high sensitivity and specificity across diverse populations and disease stages, and many biomarkers show lower sensitivity for early-stage disease, raising the risk of false negatives that provide false reassurance and false positives that trigger costly, anxiety-inducing confirmatory workups. Reimbursement remains uneven and immature across geographies and applications, and many advanced tests are offered as self-pay or laboratory-developed tests without broad payer or public coverage, constraining access and return on investment. Regulatory pathways are still evolving, particularly for novel and multi-analyte tests, lengthening development timelines and adding uncertainty, and the absence of approval for many tests limits guideline inclusion. Standardization and harmonization gaps across platforms, assays, and reference ranges complicate comparability and clinical interpretation, and the need for confirmatory imaging or tissue testing in some settings limits standalone use. High costs of advanced platforms and the need for specialized infrastructure and expertise constrain adoption, particularly in lower-resource settings, and data-privacy, governance, and equity considerations add complexity. Clinician and patient awareness remains uneven, and uncertainty about real-world impact on outcomes pending long-term evidence tempers uptake. Together, these validation, reimbursement, regulatory, standardization, and infrastructure barriers moderate the pace of growth, even as the underlying drivers of disease burden and non-invasive testing remain firmly intact.
Blood Based Biomarkers Market Segment Analysis
The Blood Based Biomarkers Market by Type (Genetic Biomarkers, Protein Biomarkers, Cellular Biomarkers, Metabolite Biomarkers), Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Metabolic and Other Diseases), Technology (Immunoassays, Polymerase Chain Reaction, Next-Generation Sequencing, Mass Spectrometry, Others), End User (Hospital and Diagnostic Laboratories, Reference Laboratories, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies), and Geography (North America, Europe, Asia-Pacific, Rest of World).
By Type
Dominant Subsegment: Genetic Biomarkers. The genetic biomarkers category is expected to dominate the market.
Dominant: Genetic Biomarkers ~ 41%
The genetic biomarkers segment accounted for 41% of the Blood Based Biomarkers market in 2025. Genetic biomarkers are the leading type because circulating tumor DNA, cell-free DNA, microRNA, and other nucleic-acid markers anchor the high-value, fast-growing field of liquid biopsy in oncology, the largest application for blood-based biomarkers. These markers detect the presence of tumors, guide treatment selection, identify resistance mutations, and monitor minimal residual disease and recurrence, capturing substantial clinical and commercial value. The rising incidence of cancer, advances in sequencing and digital polymerase chain reaction, and growing demand for personalized medicine reinforce the segment's dominance, as genetic profiles increasingly direct targeted therapy. Protein biomarkers form a very large and established category, spanning cardiac troponin, prostate-specific antigen, and the phosphorylated tau markers driving the Alzheimer's blood-test wave, while cellular biomarkers, including circulating tumor cells, are the fastest-growing type as genomics and proteomics research and precision medicine expand, and metabolite biomarkers support metabolic disease. Nonetheless, the value, growth, and oncology centrality of genetic biomarkers secure their leadership across the forecast period.
By Application
Dominant Subsegment: Oncology. The oncology category is expected to dominate the market.
Dominant: Oncology ~ 39%
The oncology segment accounted for 39% of the Blood Based Biomarkers market in 2025. Oncology is the leading application because blood-based biomarkers are central to cancer detection, treatment selection, recurrence monitoring, and companion diagnostics, and because the rising global cancer burden continuously expands testing volumes. Liquid biopsy and circulating tumor DNA testing enable non-invasive detection of actionable mutations, minimal residual disease monitoring, and recurrence surveillance, and established tests detect circulating tumor DNA to guide therapy without tissue biopsy. The breadth of cancer types, the large and growing patient population, and strong research and development investment anchor the segment's dominance. Cardiovascular disease is a large application, anchored by high-volume cardiac biomarkers such as troponin for heart-attack detection and risk stratification, while neurological diseases are the fastest-growing application, propelled by the Alzheimer's blood-test wave and demand for non-invasive neurodegenerative diagnostics, and metabolic and other diseases contribute through markers such as glucose and glycated hemoglobin. Nonetheless, the scale, value, and research momentum of oncology secure its leadership across the forecast period.
By End User
Dominant Subsegment: Hospital and Diagnostic Laboratories. The hospital and diagnostic laboratories category is expected to dominate the market.
Dominant: Hospital and Diagnostic Laboratories ~ 48%
The hospital and diagnostic laboratories segment accounted for 48% of the Blood Based Biomarkers market in 2025. Hospital and diagnostic laboratories are the largest end user because they perform the overwhelming majority of blood-based biomarker tests, from routine cardiac and oncology markers to the new generation of neurological assays, and have the platforms, throughput, and clinical integration to deliver them at scale. These laboratories order, run, and interpret tests, integrate results into patient care, and coordinate follow-up, making them central to clinical adoption, and the recent nationwide laboratory launches of Alzheimer's blood tests illustrate their pivotal role. Reference laboratories are a large and fast-growing end user, performing complex, specialized, and high-sensitivity assays such as liquid biopsy and ultra-sensitive neurological testing, while academic and research institutes drive biomarker discovery and validation, and pharmaceutical and biotechnology companies use blood-based biomarkers for clinical trials and companion diagnostics. Nonetheless, the volume, infrastructure, and clinical centrality of hospital and diagnostic laboratories secure their leadership across the forecast period.
Blood Based Biomarkers Market Region Analysis
Dominant Region: North America
North America accounted for 44% of the global Blood Based Biomarkers market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects advanced healthcare infrastructure, high healthcare spending, and strong adoption of advanced diagnostics, a high burden of cancer and neurological disease, and the concentration of leading diagnostics companies, particularly in the United States. North America leads in regulatory clearances and clinical adoption, exemplified by the 2025 FDA clearance of the first blood test to aid Alzheimer's diagnosis and its rapid nationwide laboratory launch, the clearance of plasma tau tests for primary care, and earlier clearances of point-of-care brain-injury biomarker tests. The region hosts a deep pool of diagnostics leaders and liquid-biopsy innovators, robust oncology and neurology pipelines, significant research funding, and growing payer engagement, supported by professional-society guidelines endorsing blood-based testing. Strong infrastructure, regulatory leadership, and innovation anchor the region's continued leadership across the forecast period.
Dominant: North America ~ 44% (Largest)
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest-growing region in the Blood Based Biomarkers market. The region's elevated CAGR is driven by a large and aging population, a rising burden of cancer, cardiovascular, and neurological disease, expanding healthcare access and investment, and growing adoption of advanced diagnostics across China, Japan, India, South Korea, and Australia. Increasing awareness of liquid biopsy and non-invasive testing, expanding laboratory infrastructure, government initiatives to improve early diagnosis, and strong regional diagnostics and research activity are accelerating adoption. Japan in particular is advancing neurodegenerative-disease diagnostics, and regional players are scaling cost-effective testing. Rising chronic-disease prevalence, growing healthcare expenditure, and expanding access position Asia-Pacific as the principal source of incremental growth over the forecast period.
Regional Commentary
North America
North America accounted for 44% of the global Blood Based Biomarkers market revenue in 2025. The United States dominates on the strength of advanced infrastructure, high healthcare spending, regulatory leadership including the first FDA-cleared Alzheimer's blood test, a dense base of diagnostics and liquid-biopsy companies, and strong research funding, while Canada contributes through oncology liquid-biopsy and neurology adoption.
Europe
Europe is a large and advanced regional market, led by Germany, the United Kingdom, France, Italy, and Spain. Growth is supported by strong public health systems, rising awareness of liquid biopsy and blood-based testing, active neurodegenerative-disease research, and a robust base of diagnostics companies, while the in vitro diagnostic regulation shapes the evidence requirements and adoption of new tests across the region.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by a large aging population, rising cancer, cardiovascular, and neurological disease burden, expanding healthcare access and investment, and growing adoption of advanced diagnostics across China, Japan, India, South Korea, and Australia. Regional diagnostics players scale cost-effective testing, while government early-diagnosis initiatives and neurodegenerative-disease research broaden access.
Rest of World
The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging contributor. A rising burden of cancer and chronic disease, expanding healthcare access, and growing interest in non-invasive diagnostics are creating early demand, while partnerships, laboratory capacity building, and improving reimbursement gradually extend access to blood-based biomarker testing across these markets over the forecast period.
Blood Based Biomarkers Market Competitive Landscape
The Blood Based Biomarkers market is classified as Moderately Concentrated. A group of large diagnostics leaders, including Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific, holds substantial share through broad immunoassay and molecular platforms, extensive clinical evidence, and global distribution, while a dynamic field of laboratory networks and specialized innovators, including Quest Diagnostics, Labcorp, Quanterix, Fujirebio, Guardant Health, and other liquid-biopsy and neurodegenerative-biomarker players, intensifies competition through novel biomarkers and advanced detection technologies.
The competitive landscape can be evaluated across the following dimensions:
- Market concentration: Moderately concentrated, with large diagnostics leaders alongside a dynamic field of laboratory networks and specialized liquid-biopsy and neuro innovators.
- Leading players: Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific anchor the top tier through broad platforms and clinical evidence.
- Geographic reach: Leaders operate global commercial and laboratory networks, with strong positions across North America, Europe, and Asia-Pacific.
- Product portfolio strength: Top players hold integrated immunoassay, molecular, and sequencing portfolios spanning oncology, cardiology, and neurology.
- Pipeline and evidence strength: Regulatory clearances and large clinical datasets, such as the first FDA-cleared Alzheimer's blood tests, are decisive competitive assets.
- Strategic partnerships: Collaborations between diagnostics and pharmaceutical companies, such as Biogen with Beckman Coulter and Fujirebio, accelerate test development.
- M&A activity: Active consolidation as players acquire biomarker technologies and liquid-biopsy and neurodegenerative capabilities to broaden portfolios.
- Technology platforms: Ultra-sensitive immunoassays, next-generation sequencing, digital polymerase chain reaction, and mass spectrometry differentiate providers.
- Innovation focus: Liquid biopsy and circulating tumor DNA, plasma tau neurological markers, multi-biomarker panels, and AI-driven interpretation.
Blood Based Biomarkers Market Recent Developmental Activities
In May 2025, Fujirebio Holdings, Inc., received FDA 510(k) clearance for its Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio test, the first FDA-cleared blood-based in vitro diagnostic in the United States to aid identification of amyloid pathology associated with Alzheimer's disease. Strategic significance: Opened the era of FDA-cleared Alzheimer's blood testing and accelerated clinical adoption.
In August 2025, Laboratory Corporation of America Holdings, launched the FDA-cleared Alzheimer's plasma biomarker blood test nationwide, broadening patient access across the United States. Strategic significance: Demonstrated rapid laboratory-network scale-up of Alzheimer's blood testing and expanded clinical reach.
Blood Based Biomarkers Market Segmentation
Blood Based Biomarkers Market by Type
- Genetic Biomarkers
- Protein Biomarkers
- Cellular Biomarkers
- Metabolite Biomarkers
Blood Based Biomarkers Market by Application
- Oncology
- Cardiovascular Diseases
- Neurological Diseases
- Metabolic and Other Diseases
Blood Based Biomarkers Market by Technology
- Immunoassays
- Polymerase Chain Reaction
- Next-Generation Sequencing
- Mass Spectrometry
- Others
Blood Based Biomarkers Market by Sample Type
- Whole Blood
- Plasma
- Serum
Blood Based Biomarkers Market by End User
- Hospital and Diagnostic Laboratories
- Reference Laboratories
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
Blood Based Biomarkers Market by Geography
- North America Blood Based Biomarkers Market
- United States Blood Based Biomarkers Market Size in USD million (2023-2034)
- Canada Blood Based Biomarkers Market Size in USD million (2023-2034)
- Mexico Blood Based Biomarkers Market Size in USD million (2023-2034)
- Europe Blood Based Biomarkers Market
- Germany Blood Based Biomarkers Market Size in USD million (2023-2034)
- United Kingdom Blood Based Biomarkers Market Size in USD million (2023-2034)
- France Blood Based Biomarkers Market Size in USD million (2023-2034)
- Italy Blood Based Biomarkers Market Size in USD million (2023-2034)
- Spain Blood Based Biomarkers Market Size in USD million (2023-2034)
- Rest of Europe Blood Based Biomarkers Market Size in USD million (2023-2034)
- Asia-Pacific Blood Based Biomarkers Market
- China Blood Based Biomarkers Market Size in USD million (2023-2034)
- Japan Blood Based Biomarkers Market Size in USD million (2023-2034)
- India Blood Based Biomarkers Market Size in USD million (2023-2034)
- South Korea Blood Based Biomarkers Market Size in USD million (2023-2034)
- Australia Blood Based Biomarkers Market Size in USD million (2023-2034)
- Rest of Asia-Pacific Blood Based Biomarkers Market Size in USD million (2023-2034)
- Rest of the World (RoW) Blood Based Biomarkers Market
- Middle East Blood Based Biomarkers Market Size in USD million (2023-2034)
- Africa Blood Based Biomarkers Market Size in USD million (2023-2034)
- South America Blood Based Biomarkers Market Size in USD million (2023-2034)
Key Takeaways from the Blood Based Biomarkers Market Report Study
- Market size analysis for the current blood based biomarkers market size (2025), and market forecast for 9 years (2026 to 2034).
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
- Key companies dominating the global blood based biomarkers market.
- Various opportunities available for competitors in the blood based biomarkers market space.
- What are the top-performing segments in 2025? How will these segments perform in 2034?
- Which are the top-performing regions and countries in the current blood based biomarkers market scenario?
- Which are the regions and countries where companies should concentrate their opportunities for blood based biomarkers market growth in the future?
Target audience who can benefit from this blood based biomarkers market report study
- Blood Based Biomarkers product providers
- Research organizations and consulting companies
- Blood Based Biomarkers-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in blood based biomarkers
- Various end-users who want to know more about the blood based biomarkers market and the latest technological developments in the blood based biomarkers market.
Frequently Asked Questions:
Q1. What is the growth rate of the Blood Based Biomarkers market?
The Blood Based Biomarkers market is projected to expand at a CAGR of 9.0% during the forecast period from 2026-2034.
Q2. What is the market size of the Blood Based Biomarkers market?
The Blood Based Biomarkers market is estimated at USD 8.50 billion in 2025 and is projected to reach USD 18.50 billion by 2034.
Q3. Which region dominates the Blood Based Biomarkers market?
North America dominated the Blood Based Biomarkers market with a 44% share of global revenue in 2025, supported by advanced infrastructure, high healthcare spending, regulatory leadership including the first FDA-cleared Alzheimer's blood test, and a dense base of diagnostics and liquid-biopsy companies. Asia-Pacific is the fastest-growing region over the forecast period.
Q4. What are the key drivers of the Blood Based Biomarkers market?
The principal drivers are the rising global cancer burden, with the International Agency for Research on Cancer projecting cancer cases to rise from 20 million in 2022 to 35 million by 2050; the growing burden of neurological disease and the Alzheimer's blood-test wave; accelerating FDA clearances and professional-guideline support; the maturation of liquid biopsy; and the broad shift toward non-invasive, preventive testing supported by AI and multi-biomarker panels.
Q5. Who are the major players in the Blood Based Biomarkers market?
The major players include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Bio-Rad Laboratories, Inc., Quanterix Corporation, Fujirebio Holdings, Inc., and Guardant Health, Inc., among other active providers profiled in the Competitive Landscape section. Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific lead through broad platforms and clinical evidence.
Table of Contents
1. Blood Based Biomarkers Market Report Introduction
- 1.1 Scope of the Study
- 1.2 Market Segmentation
- 1.3 Market Assumptions
2. Blood Based Biomarkers Market Executive Summary
- 2.1 Market at a Glance
3. Blood Based Biomarkers Market Key Factors Analysis
- 3.1 Blood Based Biomarkers Market Drivers
- 3.1.1 Rising Cancer Burden and Liquid Biopsy
- 3.1.2 Neurological Disease and Alzheimer's Blood Tests
- 3.1.3 Regulatory Clearances and Guideline Support
- 3.1.4 Non-Invasive Testing and Molecular Advances
- 3.2 Blood Based Biomarkers Market Restraints and Challenges
- 3.2.1 Validation, Sensitivity, and Confirmatory Testing
- 3.2.2 Reimbursement and Regulatory Pathways
- 3.2.3 Standardization and Infrastructure Barriers
- 3.3 Blood Based Biomarkers Market Opportunities
- 3.3.1 Neurology, Multi-Omics, and AI Panels
- 3.3.2 Companion Diagnostics and Emerging Markets
4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
5. Regulatory Analysis
- 5.1 United States
- 5.2 Europe
- 5.3 Japan
- 5.4 China
6. Blood Based Biomarkers Market Porter's Five Forces Analysis
- 6.1 Bargaining Power of Suppliers
- 6.2 Bargaining Power of Buyers
- 6.3 Threat of New Entrants
- 6.4 Threat of Substitutes
- 6.5 Competitive Rivalry
7. Blood Based Biomarkers Market Assessment
- 7.1 By Type
- 7.1.1 Genetic Biomarkers
- 7.1.2 Protein Biomarkers
- 7.1.3 Cellular Biomarkers
- 7.1.4 Metabolite Biomarkers
- 7.2 By Application
- 7.2.1 Oncology
- 7.2.2 Cardiovascular Diseases
- 7.2.3 Neurological Diseases
- 7.2.4 Metabolic and Other Diseases
- 7.3 By Technology
- 7.3.1 Immunoassays
- 7.3.2 Polymerase Chain Reaction
- 7.3.3 Next-Generation Sequencing
- 7.3.4 Mass Spectrometry
- 7.3.5 Others
- 7.4 By Sample Type
- 7.4.1 Whole Blood
- 7.4.2 Plasma
- 7.4.3 Serum
- 7.5 By End User
- 7.5.1 Hospital and Diagnostic Laboratories
- 7.5.2 Reference Laboratories
- 7.5.3 Academic and Research Institutes
- 7.5.4 Pharmaceutical and Biotechnology Companies
- 7.6 By Geography
- 7.6.1 North America
- 7.6.1.1 United States Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.1.2 Canada Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.1.3 Mexico Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.2 Europe
- 7.6.2.1 Germany Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.2.2 United Kingdom Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.2.3 France Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.2.4 Italy Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.2.5 Spain Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.2.6 Rest of Europe Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.3 Asia-Pacific
- 7.6.3.1 China Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.3.2 Japan Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.3.3 India Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.3.4 South Korea Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.3.5 Australia Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.3.6 Rest of Asia-Pacific Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.4 Rest of World
- 7.6.4.1 Middle East Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.4.2 Africa Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.4.3 South America Blood Based Biomarkers Market Size in USD million (2023-2034)
- 7.6.1 North America
8. Blood Based Biomarkers Market Competitive Landscape
- 8.1 Market Concentration and Structure
- 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)
9. Blood Based Biomarkers Market Startup Funding and Investment Trends
10. Blood Based Biomarkers Market Company and Product Profiles
- 10.1 F. Hoffmann-La Roche Ltd
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Product Portfolio
- 10.1.5 Strategic Initiatives / Entropy
- 10.2 Abbott Laboratories
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Portfolio
- 10.2.5 Strategic Initiatives / Entropy
- 10.3 Siemens Healthineers AG
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Portfolio
- 10.3.5 Strategic Initiatives / Entropy
- 10.4 Thermo Fisher Scientific Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Portfolio
- 10.4.5 Strategic Initiatives / Entropy
- 10.5 Quest Diagnostics Incorporated
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Portfolio
- 10.5.5 Strategic Initiatives / Entropy
- 10.6 Laboratory Corporation of America Holdings
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Portfolio
- 10.6.5 Strategic Initiatives / Entropy
- 10.7 Bio-Rad Laboratories, Inc.
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Portfolio
- 10.7.5 Strategic Initiatives / Entropy
- 10.8 Quanterix Corporation
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Portfolio
- 10.8.5 Strategic Initiatives / Entropy
- 10.9 Fujirebio Holdings, Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Portfolio
- 10.9.5 Strategic Initiatives / Entropy
- 10.10 Guardant Health, Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Snapshot
- 10.10.3 Financial Overview
- 10.10.4 Product Portfolio
- 10.10.5 Strategic Initiatives / Entropy
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.
